Eyegate to price its IPO of 1,923,077 shares at $12.00 to $14.00

Aegis Capital will assist in selling company’s common stock in deal

By Devika Patel

Knoxville, Tenn., Sept. 12 – Eyegate Pharmaceuticals, Inc. will sell 1,923,077 common shares in its initial public offering with a 45-day greenshoe of 288,462 additional shares, according to a free-writing prospectus filed Friday with the Securities and Exchange Commission. The deal was announced July 30.

The shares will be sold at a price expected to fall between $12.00 and $14.00 per share.

Aegis Capital Corp. is the bookrunning manager.

Proceeds will be used for clinical trials, safety trials, proof-of concept trials, preclinical studies, working capital and other general corporate purposes.

The pharmaceutical company is based in Waltham, Mass. The company intends to list its common stock on the Nasdaq under the symbol “EYEG.”

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.